ATE274499T1 - Spiro verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation - Google Patents

Spiro verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation

Info

Publication number
ATE274499T1
ATE274499T1 AT96936093T AT96936093T ATE274499T1 AT E274499 T1 ATE274499 T1 AT E274499T1 AT 96936093 T AT96936093 T AT 96936093T AT 96936093 T AT96936093 T AT 96936093T AT E274499 T1 ATE274499 T1 AT E274499T1
Authority
AT
Austria
Prior art keywords
aggregation
platele
fibrinogen
inhibitors
dependent
Prior art date
Application number
AT96936093T
Other languages
English (en)
Inventor
Matthew J Fisher
Joseph A Jakubowski
John J Masters
Jeffrey T Mullaney
Michael Paal
Gerd Ruehter
Kenneth J Ruterbories
Robert M Scarborough
Theo Schotten
Wolfgang Stenzel
Original Assignee
Lilly Co Eli
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Millennium Pharm Inc filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE274499T1 publication Critical patent/ATE274499T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT96936093T 1995-09-29 1996-09-27 Spiro verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation ATE274499T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US455795P 1995-09-29 1995-09-29
PCT/US1996/015703 WO1997011940A1 (en) 1995-09-29 1996-09-27 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation

Publications (1)

Publication Number Publication Date
ATE274499T1 true ATE274499T1 (de) 2004-09-15

Family

ID=21711385

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96936093T ATE274499T1 (de) 1995-09-29 1996-09-27 Spiro verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation

Country Status (10)

Country Link
US (3) US6291469B1 (de)
EP (1) EP0854869B1 (de)
JP (1) JPH11512723A (de)
AT (1) ATE274499T1 (de)
AU (1) AU713235B2 (de)
CA (1) CA2233204A1 (de)
DE (1) DE69633245T2 (de)
ES (1) ES2227612T3 (de)
NZ (1) NZ320963A (de)
WO (1) WO1997011940A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4562799A (en) 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
ATE250604T1 (de) * 1999-10-27 2003-10-15 Millennium Pharm Inc Pyridyl enthaltende spirocyclische verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation
EP1236726B1 (de) 1999-12-03 2004-12-01 Ono Pharmaceutical Co., Ltd. Triazaspiro[5.5]undecan-derivate und drogen, die dasselbe als aktiven inhaltsstoff enthalten
RU2265021C2 (ru) * 1999-12-03 2005-11-27 Оно Фармасьютикал Ко., Лтд. Производные триазаспиро[5,5]ундекана (варианты), фармацевтическая композиция и способ регулирования хемокина/рецептора хемокина
RU2002126554A (ru) 2000-03-06 2004-03-20 Акадиа Фармасьютикалз, Инк. (Us) Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
US6482829B2 (en) * 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
EP1378509A4 (de) 2001-03-19 2009-03-25 Ono Pharmaceutical Co ARZNEIMITTEL MIT TRIAZASPIRO ç5.5]UNDECANDERIVATEN ALS WIRKSTOFF
CZ20032531A3 (cs) 2001-03-19 2004-01-14 Ono Pharmaceutical Co., Ltd. Derivát triazaspiro[5.5]undekanu a farmaceutická kompozice obsahující tento derivát jako účinnou složku
CN1264847C (zh) 2001-05-14 2006-07-19 弗·哈夫曼-拉罗切有限公司 1－氧杂－3,9－二氮杂－螺[5.5]十一－2－酮衍生物及其作为神经激肽受体拮抗剂的用途
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
WO2003057698A2 (en) 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Spiroazacyclic compounds as monoamine receptor modulators
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
CN100509804C (zh) 2002-06-24 2009-07-08 阿卡蒂亚药品公司 N-取代哌啶衍生物作为血清素受体试剂
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
JP2006505585A (ja) * 2002-10-18 2006-02-16 モリケム メディシンズ， インコーポレイテッド ランチビオティクスで眼乾燥症を処置する方法
PT1587789E (pt) 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
WO2004092169A1 (ja) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
US20070185077A1 (en) * 2003-07-15 2007-08-09 Washington University Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
CA2573951A1 (en) * 2003-07-18 2005-01-27 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
WO2005023810A1 (en) * 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
JPWO2005047286A1 (ja) * 2003-11-13 2007-05-31 小野薬品工業株式会社 スピロ複素環化合物
RU2006132465A (ru) 2004-02-10 2008-03-20 Ф.Хоффманн-Ля Рош Аг (Ch) Модуляторы хемокинового рецептора ccr5
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
EP1753445A4 (de) * 2004-05-06 2009-05-20 Molichem Medicines Inc Behandlung von augenerkrankungen und augenleiden mit lantibiotischen zusammensetzungen
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
CA2584502A1 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
US7709642B2 (en) 2004-06-25 2010-05-04 Virochem Pharma, Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
WO2006006490A1 (ja) * 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
EP1790639B1 (de) * 2004-08-27 2014-03-26 Ono Pharmaceutical Co., Ltd. Spirocyclische verbindungen und ihre verwendung als cxcr4-antagonisten
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
JP4996467B2 (ja) 2004-09-27 2012-08-08 アカディア ファーマシューティカルズ インコーポレイテッド Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US8110581B2 (en) 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
ES2547724T3 (es) * 2004-11-10 2015-10-08 Incyte Corporation Compuestos de lactama y su uso como productos farmacéuticos
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
EP1889622A4 (de) 2005-05-31 2009-12-23 Ono Pharmaceutical Co Spiropiperidinverbindung und deren medizinische verwendung
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
WO2007065256A1 (en) * 2005-12-06 2007-06-14 Virochem Pharma Inc. Novel spiropiperidine compounds and methods for the modulation of chemokine receptor activity
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
PE20081735A1 (es) * 2007-02-01 2009-01-18 Glaxo Group Ltd Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios
JP2010517966A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド 摂食障害の処置のための１−オキサ−３−アザスピロ（４．５）デカン−２−オンおよび１−オキサ−３，８−ジアザスピロ（４．５）デカン−２−オン誘導体
CN101255161B (zh) * 2007-02-28 2011-07-20 上海药明康德新药开发有限公司 9-pg-3,9-二氮杂-2,4-二氧代-螺[5.5]十一烷的合成方法
HRP20130713T1 (en) 2007-03-19 2013-09-30 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
WO2008119663A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
WO2009039431A2 (en) * 2007-09-21 2009-03-26 Neurogen Corporation Substituted aryl-fused spirocyclic amines
WO2009097405A2 (en) * 2008-01-30 2009-08-06 Neurogen Corporation Compounds and methods for preparing diazaspiro derivatives
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
WO2012064642A1 (en) * 2010-11-08 2012-05-18 Glaxosmithkline Llc Fatty acid synthase inhibitors
KR101923367B1 (ko) 2011-02-02 2018-12-04 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
CN103517910B (zh) * 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
EP2744333B1 (de) * 2011-08-19 2016-10-05 Glaxosmithkline Intellectual Property (No. 2) Limited Fettsäuresynthasehemmer
WO2013052716A1 (en) * 2011-10-07 2013-04-11 Glaxosmithkline Llc Fatty acid synthase inhibitors
NZ627259A (en) * 2012-01-16 2016-12-23 Vertex Pharma Pyran-spirocyclic piperidine amides as modulators of ion channels
WO2014008223A2 (en) * 2012-07-03 2014-01-09 Glaxosmithkline Llc Fatty acid synthase inhibitors
FR3000064A1 (fr) * 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
WO2015017305A1 (en) * 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibitors of the renal outer medullary potassium channel
EP3063142B1 (de) 2013-10-31 2019-01-30 Merck Sharp & Dohme Corp. Inhibitoren des renalen kaliumkanals der äusseren medulla
WO2015096035A1 (en) * 2013-12-24 2015-07-02 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
EP3134408B1 (de) * 2014-04-22 2020-08-12 Merck Sharp & Dohme Corp. Faktor-xia-hemmer
CN104530080B (zh) * 2014-12-10 2017-01-11 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
PL3325444T3 (pl) 2015-07-20 2021-12-06 Acadia Pharmaceuticals Inc. Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (de) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin allein oder in kombination zur verwendung in der behandlung von morbus-alzheimer-psychose
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
CN111533739B (zh) * 2020-05-08 2023-05-05 上海皓鸿生物医药科技有限公司 3-烷基-3,9-二氮杂螺[5,5]十一烷的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1993013101A1 (fr) 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
US5786373A (en) 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
ATE188379T1 (de) 1992-10-14 2000-01-15 Merck & Co Inc Fibrinogenrezeptor-antagonisten
JPH08504194A (ja) 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
PL310386A1 (en) 1993-02-22 1995-12-11 Merck & Co Inc Antagonists of factor i receptors
US5441952A (en) 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
US5817756A (en) * 1993-09-09 1998-10-06 Scios Inc. Pseudo- and non-peptide bradykinin receptor antagonists
CA2134192A1 (en) * 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DK0730590T3 (da) * 1993-11-24 2001-03-19 Du Pont Pharm Co Isoxazolin og isozazol fibrinogenreceptorantagonister
US5451578A (en) * 1994-08-12 1995-09-19 Merck & Co., Inc. Fibrinogen receptor antagonists
US5739336A (en) * 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives

Also Published As

Publication number Publication date
AU7382896A (en) 1997-04-17
EP0854869B1 (de) 2004-08-25
AU713235B2 (en) 1999-11-25
JPH11512723A (ja) 1999-11-02
ES2227612T3 (es) 2005-04-01
CA2233204A1 (en) 1997-04-03
DE69633245T2 (de) 2005-09-08
US6528534B2 (en) 2003-03-04
NZ320963A (en) 1999-08-30
US20030171373A1 (en) 2003-09-11
DE69633245D1 (de) 2004-09-30
EP0854869A1 (de) 1998-07-29
MX9802379A (es) 1998-08-30
WO1997011940A1 (en) 1997-04-03
US6693109B2 (en) 2004-02-17
US20020013325A1 (en) 2002-01-31
US6291469B1 (en) 2001-09-18

Similar Documents

Publication Publication Date Title
ATE274499T1 (de) Spiro verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation
DE60005545D1 (de) Pyridyl enthaltende spirocyclische verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
ATE178614T1 (de) Zyklische verbindungen zur verwendung als inhibitoren des glycoprotein iib/iiia
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
EP1284260A4 (de) Tyrosin-phosphatase inhibitoren
EP0731106A4 (de) Neue peptid-derivate
EP1622616A4 (de) Hemmer der akt aktivität
ATE165825T1 (de) Phenyl heterocyclen als cyclooxygenase-2 inhibitoren
DK1311482T3 (da) Ikke-imidazolaryloxypiperidiner som H3-receptorligander
BRPI0612141A2 (pt) derivados de quinuclidina substituìdos com biciclo-heterociclos fundidos
DE69417012D1 (de) Cyclobutan-derivate als inhibitoren der squalen-synthetase und der protein-farnesyltransferase
FI970246A7 (fi) Dihydrobentsofuraanit
EP1612204A4 (de) Hydrazon-derivate
WO2004069793A3 (en) Novel 2-substituted cyclic amines as calcium sensing receptor modulators
ATE230398T1 (de) Substituierte heterocyklische derivate, verwendbar als plättchenaggregationshemmstoffe
PE20010751A1 (es) Quinolin-2-ona como inhibidores de las proteinas resistentes a multiples farmacos
ATE215074T1 (de) Piperazinone als inhibitoren von blutplattchenaggregation
ATE368040T1 (de) Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase- inhibitoren
ATE311388T1 (de) Pyrimidotriazine als phosphataseinhibitoren
DE60318826D1 (de) Alkoxypyridinderivate
DE60011269D1 (de) Azaidole mit serotonin rezeptor affinität
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
DK0656001T3 (da) Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere
PE20000734A1 (es) Compuestos heterociclicos derivados de furopiridina y su uso terapeutico

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties